A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery

Abroad (travel likely)Recruiting

Conditions

Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
Contact: Study coordinator (Minna Lee, MD) · 646-888-6898

Study leads

Minna Lee, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

Advanced Solid Tumor · Advanced Breast Cancer · Advanced Ovarian Cancer

Abroad (travel likely)RecruitingPHASE1

Birmingham, United States · Fullerton, United States

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

HR+/HER2- Breast Cancer

Abroad (travel likely)RecruitingPHASE3

Birmingham, United States · Anchorage, United States

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

High Grade Epithelial Ovarian Cancer · High Grade Serous Ovarian Cancer · Primary Peritoneal Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Phoenix, United States · Tucson, United States

A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

HER2-positive Breast Cancer

Abroad (travel likely)RecruitingPHASE3

Bengbu, China · Fuyang, China